Parkinson’s Trial: Solengepras Shows Remarkable Results
Solengepras reduced average daily OFF time by 1.3 hours versus placebo after 27 days (p=0.02) in a randomized Phase...
Jon Napitupulu
Apeiron Presents First-in-Human Data for GTA182 in NSCLC
Topline readout: In an ongoing Phase 1 study of GTA182 in MTAP-deleted solid tumors, the objective response rate was...
Bioversys Launches Promising Phase 3 Trial for BV100 Drug
In a Phase 2 study in ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii, BV100 delivered a 50% relative...
Study Assesses Emrosi™ (DFD-29) Impact on Microbial Flora
In a 60-subject, randomized, double-blind, placebo-controlled Phase 1 study, 16 weeks of low-dose oral minocycline (Emrosi, 40 mg modified-release;...
Atumelnant Pivotal Trial for Adult CAH Doses First Patient
Phase 2 data for atumelnant in adults with classic congenital adrenal hyperplasia (CAH) showed rapid, substantial and sustained reductions...
Rapid Resolution Lifts Hold on Tenaya’s Gene Therapy Trial
FDA has lifted the clinical hold on Tenaya’s MyPEAK-1 Phase 1b/2a trial of TN-201 in MYBPC3-associated hypertrophic cardiomyopathy, with...
Akari Therapeutics Starts GMP Manufacturing for Phase 1 Trial
Akari Therapeutics has initiated GMP manufacturing for AKTX-101, its Trop2-targeted antibody-drug conjugate built around a proprietary spliceosome-modulating payload (PH1)....
Quantum Biopharma Completes Dosing in Lucid-MS Toxicity Study
Quantum BioPharma has completed oral dosing in 180-day chronic toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS), its preclinical remyelination...
Immuneering to Post Survival Data in Pancreatic Cancer Trial
No new efficacy data were released, but Immuneering set January 7, 2026, for a 12‑month overall survival update from...
INVIVYD Launches Phase 3 Trial for COVID Antibody VYD2311
In earlier Phase 1/2 testing, intramuscular VYD2311 given at four times the planned Phase 3 dose was well tolerated,...